Business Ortho Clinical Diagnostics Agrees to $6B Quidel Acquisition On Dec 28, 2021
^ "Quidel to Present at Cowen 34th Annual Health Care Conference".^ "Quidel to buy Ortho Clinical for $6 bln to boost diagnostics portfolio | Reuters".^ "Here's Why Rapid COVID Tests Are So Expensive and Hard to Find".^ "Quidel's Sofia 2 SARS Antigen FIA Becomes First COVID-19 Antigen Test to Secure FDA Emergency Use Authorization".^ "Quidel Completes Acquisition of BioHelix Corporation".^ "Quidel Corporation (QDEL) to Buy Diagnostic Hybrids, Inc."Quidel Strikes Back With Patent Lawsuits Against Rivals". ^ "QUIDEL CORPORATION COMPLETES ACQUISITION OF LITMUS CONCEPTS".^ "Quidel Corporation Completes Acquisition of Metra Biosystems ".resigns", The Los Angeles Times, March 30, 1988. ^ Kraul, Chris, "The founder and chairman of Quidel.Queering Reproduction: Achieving Pregnancy in the Age of Technoscience. This article incorporates text from this source, which is in the public domain.
"Coronavirus (COVID-19) Update: FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients".
#ORTHO QUIDEL FULL#
^ "Quidel Reports Fourth Quarter and Full Year 2019 Financial Results".Plunkett's Health Care Industry Almanac 2009 (E-Book): Health Care Industry Market Research, Statistics, Trends and Leading Companies. ĭuring 2011, the US Food and Drug Administration (FDA) and the European Conformity Mark provided Quidel with 510(k) clearance for selling Sofia Analyzer, and another 510(k) clearance for the Quidel Molecular hMPV Assay. These products include assays such as QuickVue, Thyretain and the new Sofia and AmpliVue brands, which focus on diagnosing influenza, thyroid disease, and many other diseases, and can improve the healthcare quality of hospitals. Quidel's current products fall generally into these categories: (1) lateral flow, where it focuses on infectious disease and reproductive health (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology (3) micro-titer production, with a focus on bone and complement pathway markets (4) fluorescent immunoassay products (Sofia) and (5) molecular diagnostic products. Quidel's core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, and molecular assay development. Since its merger, Quidel has expanded its product base through internal development and acquisition with a focus on increasing its research and development efforts to accelerate the rate of new product introductions. The following is an illustration of the company's major mergers and acquisitions and historical predecessors: In December 2021, Quidel announced it would acquire Ortho Clinical Diagnostics Holdings for $6 billion in cash and stock, increasing the range of COVID-19 antigen and antibody tests the business is able to offer. In May 2020, Quidel’s Sofia 2 SARS Antigen FIA has become the first COVID-19 antigen test to be granted Emergency Use Authorization (EUA) by the FDA, approved by former Quidel employee Tim Stenzel. In 2013, Quidel acquired BioHelix Corporation, established in 2004, and was to pay $10 million to the BioHelix shareholders. a privately held in vitro diagnostic company. In 2010, Quidel acquired Diagnostic Hybrids, Inc. That same month, Quidel countersued against Inverness. In February 2004, Inverness Medical Innovations sued Quidel for patent infringement. In 2000, Quidel acquired Litmus Concepts, Inc., a privately held in vitro diagnostic company. In 1999, Quidel acquired Metra Biosystems, Inc.to participate in bone health assessment.
#ORTHO QUIDEL LICENSE#
Quidel agreed to buy a product license and pay royalties on its product sales. Quidel had been accused of infringing patents on Becton's strep and chlamydia products. On JQuidel settled a lawsuit with Becton Dickinson. Katz, a founder and chief scientific officer at Quidel, resigned to devote his energies to the Medical Biology Institute, a nonprofit research group in La Jolla, California that is closely allied with Quidel. Quidel Corporation was formed in 1991 when Quidel and Monoclonal Antibodies merged. Katz, M.D., commencing operations in 1981 and launched its first products in 1984. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs. Food and Drug Administration (FDA) has issued the first emergency use authorization (EUA) for a COVID-19 antigen test, a new category of tests for use in the ongoing pandemic. QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.
0 kommentar(er)
